v3.26.1
Segment Information (Tables)
3 Months Ended
Mar. 31, 2026
Segment Information  
Schedule of sales, cost of goods sold and gross profit by segment

For the three months ended March 31, 2026, the Company’s segment gross profit was comprised of the following (in thousands):

Women's Health

Cardiovascular

Total

Net sales

$

2,089

$

1,025

$

3,114

Cost of goods sold, excluding intangible asset amortization

891

151

1,042

Segment gross profit

$

1,198

$

874

$

2,072

For the three months ended March 31, 2025, the Company’s segment gross profit was comprised of the following (in thousands):

Women's Health

Cardiovascular

Total

Net sales

$

2,625

$

326

$

2,951

Cost of goods sold, excluding intangible asset amortization

1,173

127

1,300

Segment gross profit

$

1,452

$

199

$

1,651

Reconciliation of segment gross profit to the consolidated loss before provision for income taxes

The following table is a reconciliation of segment gross profit to the consolidated loss before provision for income taxes for the three months ended March 31, 2026 and 2025, (in thousands):

Three Months Ended

March 31, 

  ​ ​ ​

2026

2025

Segment gross profit

$

2,072

$

1,651

Adjustments:

Intangible asset amortization expense

(270)

(269)

Sales and marketing

(1,480)

(995)

General and administrative

(4,091)

(3,721)

Research and development

(1,973)

(871)

Litigation costs, net

(606)

(2,572)

Loss from operations

 

(6,348)

(6,777)

Interest (income) expense, net

 

(108)

184

Loss (gain) on revaluation of warrant liability

1,655

(5,187)

Other (income) expense, net

 

(71)

105

Loss from continuing operations before provision for income taxes

 

$

(7,824)

$

(1,879)